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Abstract
Background: Complex traumatic injuries sustained by military personnel, particularly when involving extremities,
often result in infectious complications and substantial morbidity. One factor that may further impair patient
recovery is the persistence of infections. Surface-attached microbial communities, known as biofilms, may play a role
in hindering the management of infections; however, clinical data associating biofilm formation with persistent or
chronic infections are lacking. Therefore, we evaluated the production of bacterial biofilms as a potential risk factor
for persistent infections among wounded military personnel.
Methods: Bacterial isolates and clinical data from military personnel with deployment-related injuries were collected
through the Trauma Infectious Disease Outcomes Study. The study population consisted of patients with diagnosed
skin and soft-tissue infections. Cases (wounds with bacterial isolates of the same organism collected 14 days apart)
were compared to controls (wounds with non-recurrent bacterial isolates), which were matched by organism and
infectious disease syndrome. Potential risk factors for persistent infections, including biofilm formation, were examined in
a univariate analysis. Data are expressed as odds ratios (OR; 95% confidence interval [CI]).
Results: On a per infected wound basis, 35 cases (representing 25 patients) and 69 controls (representing 60 patients)
were identified. Eight patients with multiple wounds were utilized as both cases and controls. Overall, 235 bacterial
isolates were tested for biofilm formation in the case–control analysis. Biofilm formation was significantly associated
with infection persistence (OR: 29.49; CI: 6.24-infinity) in a univariate analysis. Multidrug resistance (OR: 5.62; CI: 1.02-56.92),
packed red blood cell transfusion requirements within the first 24 hours (OR: 1.02; CI: 1.01-1.04), operating room visits
prior to and on the date of infection diagnosis (OR: 2.05; CI: 1.09-4.28), anatomical location of infected wound (OR: 5.47;
CI: 1.65-23.39), and occurrence of polymicrobial infections (OR: 69.71; CI: 15.39-infinity) were also significant risk factors for
persistent infections.
Conclusions: We found that biofilm production by clinical strains is significantly associated with the persistence of
wound infections. However, the statistical power of the analysis was limited due to the small sample size, precluding a
multivariate analysis. Further data are needed to confirm biofilm formation as a risk factor for persistent wound infections.
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Background
Due to the usage of improvised explosive devices com-
bined with the utilization of body armor protecting the
abdomen and thorax during the recent conflicts in Iraq
and Afghanistan (Operations Iraqi Freedom and Enduring
Freedom), complex extremity wounds are prevalent among
military personnel with deployment-related injuries. This
injury pattern often results in infectious complications with
considerable morbidity (e.g., limb amputation), extended
periods of rehabilitation, and high utilization of hospital re-
sources [1-8]. The prognosis of wounded military personnel
is further impacted when infections persist or recur despite
appropriate antimicrobial and surgical treatment.
Presently, few data related to infection persistence
among military personnel are available [5,9]. An assess-
ment of 664 United States (U.S.) service members with
extremity injuries reported that 15% of patients devel-
oped osteomyelitis, of which 17% experienced an infec-
tion recurrence following initial treatment [5]. Among a
cohort of 161 civilian patients who sustained traumatic
injuries resulting in amputations, 16% had at least one
rehospitalization due to an infection and 6.5% had un-
healed soft-tissue at the end of the 24-month follow-up
period [10]. Moreover, an analysis of 454 civilian patients
with osteomyelitis, primarily resulting from soft-tissue
wounds and surgical procedures, reported that 31% ex-
perienced an infection recurrence, of which 16% were
determined to be relapses (original pathogen), 16% rein-
fections (different pathogen), and 68% could not be spe-
cified as either a relapse or reinfection [11].
In general, deployment-related complex trauma in-
volves extensive bone and soft-tissue damage and often
requires the insertion of artificial materials to maintain
spatial orientation and anatomic alignment of bone frag-
ments necessary to achieve an acceptable level of healing
[7,10]. An unintended consequence of these procedures is
that the medical hardware required to stabilize mangled
extremities may serve as a substrate for the formation of
bacterial biofilms [12-14], which has been suggested by
clinicians to be a factor affecting wound healing and
the persistence of infections [13]. In recent years, mul-
tiple in vitro models have been developed to investigate
the interaction between biofilm formation and chronic
wounds [15-19].
According to a National Institute of Health grant an-
nouncement issued in 2002, more than 80% of human
bacterial infections are associated with biofilms [13,20].
In brief, biofilms are produced when bacteria expand
horizontally and vertically on a solid surface to form a
sessile, multicellular colony, which secretes a matrix
of protein, polysaccharides, and extracellular DNA. The
matrix allows the pathogen to circumvent the host’s
immune responses and impedes the penetration of anti-
microbials to the site of infection [12,21,22]. Extensive
physical trauma (e.g., soft-tissue damage and vascular
disruption) likely further enhances this obstruction.
Moreover, bacteria in the lower stratum of the colony
cease replication and become intrinsically resistant to
currently approved antimicrobial agents [12,22-25]. As a
result, biofilms cannot be predictably eradicated by sys-
temic antimicrobial treatment regimens and, therefore,
pose a risk for persistent wound infections, particularly
when foreign bodies or medical hardware that must be
retained for healing are present [12,13,23-29].
Despite the abundant literature confirming the exist-
ence of the biofilm phenomenon in in vitro analyses,
and the increasing acceptance of this theory of disease
among clinicians, an epidemiologic link has not been
clearly established between the risk of wound infection
persistence and the ability of pathogens to form biofilms.
In the current study, our objective was to examine bac-
terial biofilm formation and other potential risk factors
for persistent wound infections among injured military
personnel in a case–control analysis.
Methods
Study population
Data were collected from U.S. service members with
deployment-related injuries sustained between June 2009
through August 2012 and medically evacuated to Landstuhl
Regional Medical Center (LRMC) for initial care before
being transferred to a participating tertiary-care military
treatment facility (MTF) in the U.S.: Walter Reed Army
Medical Center and National Naval Medical Center in the
National Capital Region (Walter Reed National Military
Medical Center after September 2011), and Brooke
Army Medical Center in San Antonio, TX (San Antonio
Military Medical Center after September 2011). These clin-
ical data were collected through the ongoing five-year ob-
servational cohort study of short- and long-term infectious
complications following deployment-related traumatic in-
juries during the recent military conflicts in Iraq and
Afghanistan; the U.S. Department of Defense (DoD)–De-
partment of Veterans Affairs, Trauma Infectious Disease
Outcomes Study (TIDOS). As part of the TIDOS project, a
microbiological repository was established containing bac-
terial isolates collected from surveillance cultures at admis-
sion and cultures during the course of hospitalization [30].
This study was approved by the Infectious Disease Institu-
tional Review Board of the Uniformed Services University
of the Health Sciences (Bethesda, MD).
Case–control identification and investigation
Information on trauma history, injury patterns, treat-
ment, and infection characteristics for the case and
control populations was prospectively collected through
the DoD Trauma Registry (DoDTR, formerly the Joint
Theater Trauma Registry) [31] and augmented by the
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TIDOS supplemental infectious disease module. Radio-
logic studies and clinical encounters in the medical re-
cords were retrospectively reviewed to gather data on
medical hardware implantation. Bacterial isolates were
obtained from the TIDOS microbiological repository.
Data were collected from all levels of care: LRMC, U.S.
MTFs, and post-hospitalization follow-up.
As previously described [30], infections were classified
via a comprehensive review of medical records for rele-
vant clinical findings and laboratory test results, along
with the utilization of standardized definitions of the
National Healthcare Safety Network (NHSN) for noso-
comial infections [32]. The criterion for inclusion of
wounded personnel in the study population was a diag-
nosis of a skin and soft-tissue infection (SSTI) and the
collection of bacterial isolates from the infected wound
site within one day of diagnosis (+/- 24 hours). In
addition, the study population was limited to patients
with SSTIs linked to one of five bacterial organisms (i.e.,
Staphylococcus aureus, Klebsiella pneumoniae, Acineto-
bacter baumannii, Pseudomonas aeruginosa, and Escher-
ichia coli), reflecting clinical experience with causes of
persistent wound infections in this population. Cases
were identified on a per infected wound basis and re-
quired serial bacterial isolates of the same organism to
be collected at least 14 days apart following initial
diagnosis of an SSTI from the same infected wound.
Controls (infected wounds with non-recurrent growth of
bacterial isolates) were matched to cases on the basis of
organism and infectious disease syndrome (i.e., SSTI).
Due to the occurrence of blast injuries, patients fre-
quently sustained multiple wounds with different micro-
biological growth. If more than one infected wound
from a patient met the criteria for inclusion in the study
population (i.e., SSTI diagnosis and isolation of specific
bacterial organisms), the infected wounds were inde-
pendently treated as cases and controls as appropriate.
Therefore, one patient may contribute both a case and
control wound to the analysis.
Bacterial isolates and growth conditions
Bacterial isolates were recovered from frozen storage
at −80°C and serially passaged twice on 5% sheep’s
blood agar (Remel, Lenexa, KS) prior to experimental
testing. Organisms were defined as multidrug-resistant
if they exhibited resistance to at least three of the
major antibiotic classes (aminoglycosides, β-lactams,
carbapenems, and fluoroquinolones) or produced either
extended spectrum β-lactamases or K. pneumoniae
carbapenemases [33]. Antimicrobial susceptibility testing
was performed using the BD Phoenix™ system (Becton-
Dickinson, Franklin Lakes, NJ) per the manufacturer’s in-
structions. Susceptibility to antimicrobials was interpreted
according to the criteria of the Clinical Laboratory and
Standards Institute [34].
Biofilm production
Bacterial biofilms from clinical isolates of S. aureus, K.
pneumoniae, A. baumannii, P. aeruginosa, and E. coli
were formed in 96-well plates, under static conditions
for 48 hours as previously described [25]. For biofilm
growth, inoculums of approximately 108 CFU/mL were
prepared by adjusting culture grown bacterial suspen-
sions to an optical density (OD600 nm) of 0.25–0.3 and
adding 100 μL of each inoculum to individual wells of a
96-well plate. After incubation for 48 hours, wells were
gently washed one time with phosphate-buffered saline
(PBS; pH 7.4) and stained with 100 μL of 0.1% Crystal
Violet (CV) for 30 minutes at room temperature. Excess
CV was removed by gentle washing with PBS, and the
residual adherent CV was solubilized in 95% ethanol.
Biofilm biomass was quantified by measuring absorbance
of the supernatant at 570 nm. Absorbance above that
level from the positive control strain, Staphylococcus
epidermidis ATCC 12228 (ATCC, Manassas, VA), was
considered positive for biofilm formation. Each strain
was tested in triplicate and the mean value was recorded
as the absorbance.
Among isolates of A. baumannii, genes for the biofilm-
associated protein (bap) were amplified by polymerase
chain reaction according to primer sequences and condi-
tions as reported in the supplemental material (Additional
file 1: Figure S1). A visual assessment of biofilm production
among isolates lacking bap, and several representative iso-
lates containing the bap gene, was performed by confocal
laser scanning microscopy (Additional file 2: Figure S2).
Pulsed-field gel electrophoresis
Clonal relationships between bacterial strains of each in-
dividual species were assessed by pulsed-field gel elec-
trophoresis (PFGE) in accordance with the U.S. Food
and Drug Administration’s method ‘Procedure for PFGE
of Gram-negative rods’ (Version 1, 10/30/2007) and, as
previously described [35,36], using the CHEF-DRIII system
(Bio-Rad Laboratories, Hercules, CA). The endonucleases
utilized for PFGE examination of A. baumannii, S. aureus,
and P. aeruginosa isolates were ApaI, SmaI, and SpeI,
respectively, while XbaI was used for K. pneumoniae
and E. coli. Analysis of gel images was performed with
BioNumerics software (Applied Maths, Austin, TX).
Using previously established criteria [36,37], the PFGE
patterns were interpreted and grouped into pulsed-
field types (PFTs).
Statistical analysis
Comparisons were performed using Fisher’s exact, Chi-
square, and Wilcoxon Mann–Whitney tests for categorical
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and continuous variables, respectively. Exact conditional lo-
gistic regression was conducted to analyze the association
between the potential risk factors and persistent wound in-
fections for the univariate analysis. Independency between
the SSTI case and control wounds was assumed. Data are
expressed as odds ratios and 95% confidence intervals. Stat-
istical analysis was conducted using the PROC LOGISTIC
procedure from SAS® version 9.3 (SAS, Cary, NC). A value
of p < 0.05 was used to define statistical significance.
Results
Patient demographics and characteristics
From the eligible military trauma population, 35 cases
(representing 25 patients) and 69 controls (representing
60 patients) were identified. It should be noted that the
25 case and 60 control subjects included eight patients
with multiple wounds were used in both groups. Patients
included in the study were predominantly young men
(median age of 23 years) injured via a blast mechanism
(>83%) in support of Operation Enduring Freedom in
Afghanistan (>88%; Table 1). The injury severity scores
(i.e., a measure of overall anatomical injury severity
based upon body region-specific Abbreviated Injury Se-
verity Scale scores [38]) at admission to LRMC indicated
severe trauma for both the cases and controls with me-
dian values of 24 and 21, respectively. In addition, both
groups required large volume transfusions of packed red
blood cells plus whole blood (PRBC) within the first
24 hours following injury (median of 34 units for cases;
18 units for controls).
Per the study criteria, all patients were diagnosed with
skin and soft-tissue infections, of which the majority of
infections (92% of case and 88% of control patients)
were identified as deep soft-tissue versus superficial
(Table 2). Two cases and two controls were also diag-
nosed with osteomyelitis. The median time following
injury to the initial clinical diagnosis of the infection was
8 days for the cases and 12 days for the controls. Both
Table 1 Demographic characteristics and injury
circumstances of deployment-injured U.S. service
members (June 2009–August 2012)1





Age, median (IQR) 22.7 (21.6, 25.5) 23.3 (21.3, 26.5)
Male 25 (100) 56 (93.3)







25 (100) 53 (88.3)
Unknown 0 5 (8.3)
Branch of service
Marine 11 (44.0) 25 (41.6)
Army 12 (48.0) 26 (43.3)
Air Force/Navy 2 (8.0) 5 (8.3)
Injury circumstance and
severity
Blast injury, no. (%) 24 (96.0) 50 (83.3)
LRMC ISS, median
(IQR)
24 (14, 29) 21 (17, 29)
Units of PRBC transfused
within 1st 24 hours,
median (IQR)
34 (16, 83) 18 (9, 33)
IQR-interquartile range; ISS-injury severity score; LRMC-Landstuhl Regional
Medical Center; PRBC-packed red blood cells plus whole blood; SSTI-skin and
soft-tissue infections; U.S.-United States.
1Data are on a per patient basis.
2Eight patients with multiple infected wounds were utilized as both cases
and controls.
Table 2 Infection characteristics and outcomes among
deployment-injured U.S. service members (June 2009–
August 2012)1




Time from injury to
clinical diagnosis,
median days (IQR)
8.0 (5.0, 16.0) 11.5 (7.0, 21.5)
Time from injury to initial
positive culture, median
days (IQR)
8.0 (7.0, 17.0) 12.0 (7.0, 22.0)
Infection type, no. (%)3
SSTI-superficial 4 (16.0) 8 (13.3)
SSTI-deep 23 (92.0) 53 (88.3)
Osteomyelitis 2 (8.0) 2 (3.3)
Foreign body 0 1 (1.7)
Antibiotic use, no. (%)
1–14 days 4 (16.0) 18 (30.0)
15–23 days 3 (12.0) 16 (26.7)
24–43 days 7 (28.0) 10 (16.7)
>43 days 11 (44.0) 8 (13.3)
Completed during
hospitalization4
17 (68.0) 47 (78.3)
Ongoing at
discharge4




3 (12.0) 6 (10.0)
Limb loss due to
infection
2 (8.0) 3 (5.0)
Death 1 (4.0) 2 (3.3)
IQR-interquartile range; SSTI-skin and soft-tissue infection; U.S.-United States.
1Data are on a per patient basis.
2Eight patients with multiple infected wounds were utilized as both cases
and controls.
3Patients were diagnosed with multiple infected wounds.
4Data missing from one case patient.
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groups largely completed their course of antibiotics while
hospitalized (68% of cases and 78% of controls) with dura-
tions ranging from two weeks (16% and 30%, respectively)
to more than 43 days (44% and 13%, respectively). Similar
proportions of case (12%) and control patients (10%) expe-
rienced a surgical amputation during their hospitalization,
with at least half of the procedures attributed to infections.
Overall, there were three deaths among the study popula-
tion (one case and two controls).
Wound characteristics
Extremity injuries accounted for 60% of the SSTI case
wounds (37% and 23% for the lower and upper limbs,
respectively), while the groin/pelvis contributed the
remaining proportion. Among the SSTI control wounds,
65%, 13%, and 22% involved lower extremity, upper ex-
tremity, and non-extremity wound sites (i.e., groin/pel-
vis and head/chest/abdomen), respectively (Table 3).
Between the two groups, there was a significant difference
(p = 0.024) in the overall infection site profile. Regarding
the SSTI case wounds, the occurrence of polymicrobial
infections and biofilm production was significantly
greater (71% and 97%, respectively; p < 0.0001) com-
pared to the control wounds (0 and 59%, respectively).
The case wounds were also predominantly character-
ized by multidrug-resistant organisms (MDROs); how-
ever, the proportion was not significantly different
from the control wounds. Moreover, approximately
20% of both the case and control wounds required the
implantation of medical hardware.
Overall, a total of 340 bacterial cultures were collected, of
which 151 (89 from case wounds; 62 from control wounds)
grew bacterial organisms and A. baumannii was the pre-
dominant isolate among the cases (24%) and controls (30%;
Table 4). P. aeruginosa was also a major contributor (24%
and 29% for cases and controls, respectively) followed by
E. coli (9% and 19%, respectively), K. pneumoniae (8% and
1%, respectively), and S. aureus (3% and 6%, respectively).
When the bacterial isolates were compared between the
SSTI case and control wounds, there was a significant
difference in the profiles (p < 0.0001). In addition, 235
bacterial isolates linked to infections and utilized in the
case–control analysis (after selection through use of
matching criteria) were tested for multidrug resistance
(Table 5). On a per patient basis, all infections asso-
ciated with A. baumannii and K. pneumoniae were
due to multidrug-resistant isolates. Infections attri-
buted to E. coli isolates were also largely multidrug-
resistant (75% and 83% of the case and control patients,
respectively). However, S. aureus infections only de-
monstrated methicillin resistance among the case pa-
tients (67%) and P. aeruginosa isolates were generally
susceptible with both groups.
Biofilm formation
Biofilm production was assessed among the 235 isolates
utilized in the case–control analysis and a significantly
greater proportion of biofilms formed in association
with A. baumannii isolates among the cases com-
pared to the controls (p < 0.0001; Table 6). However,
there were no statistical differences regarding biofilm
Table 3 Infection characteristics among deployment-
injured U.S. service members (June 2009–August 2012)1
Characteristics SSTI Case
Wounds (N = 35)
SSTI Control





Lower extremity 13 (37.1) 45 (65.2)
Thigh 8 (22.9) 26 (37.6)
Gluteal muscles 0 4 (5.7)
Knee 1 (2.8) 4 (5.7)
Lower leg 2 (5.7) 9 (13.0)
Ankle 0 1 (1.4)
Foot 2 (5.7) 1 (1.4)
Upper extremity 8 (22.9) 9 (13.0)
Upper arm 4 (11.4) 5 (7.2)
Forearm 4 (11.4) 4 (5.7)
Non-extremity 14 (40.0) 15 (21.7)




Time from injury to 1st
culture with growth,
median days (IQR)2
12 (8, 38) 16 (7, 28) 0.989
OR visits prior to and
on date of infection
diagnosis, median (IQR)
1 (1, 1) 1 (1, 1) 0.285
Medical devices




7 (20.0) 13 (18.8) 1.000
Infection Characteristics,
No. (%)
Biofilm production 34 (97.1) 41 (59.4) <0.0001
Organisms susceptible
to empiric antibiotics




26 (74.3) 41 (59.4) 0.135
Polymicrobial
infection
25 (71.4) 0 <0.0001
IQR-interquartile range; OR-operating room; SSTI-skin and soft-tissue infections;
U.S.-United States.
1Data are on a per SSTI wound basis.
2Specific to growth of the five organisms included in the analysis:
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, and Escherichia coli.
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production with either P. aeruginosa or E. coli. Data
from K. pneumoniae and S. aureus were too few to
be analyzed.
The serial isolates of the case wounds were also exam-
ined for concordance of the PFTs and biofilm produc-
tion. The majority of the case wounds had concordant
PFTs with only nine cases (26%) reporting a PFT that
was different from the initial isolate. In addition, bacter-
ial isolates from 14 case wounds (40%) exhibited biofilm
production that was discordant from the initially isolated
sample.
Carriage of the bap gene was widespread in A. bau-
mannii, identified in 96% of isolates (Additional file 1:
Figure S1). On a per isolate basis, bap carriage was not
associated with biofilm formation, as determined by CV
uptake (p = 1.00). The three bap-negative isolates were
recovered from infectious episodes subsequent to the
initial infection with two of the isolates identified among
cultures collected from the same wound site of a single
patient on the same date. Each bap-negative isolate
matched the PFGE genotype and antimicrobial suscepti-
bility phenotype of the initial infecting isolate. Confocal
microscopy images of bap-positive and bap-negative
isolates suggested that bap may increase biofilm forma-
tion among isolates carrying this gene. Qualitatively,
biofilms appeared to form among bap-negative iso-
lates, but to a lesser degree than bap-positive isolates
(Additional file 2: Figure S2).
Univariate risk factor analysis
Site of infection (i.e., non-groin/genitalia wound versus
groin/genitalia wound), biofilm production, presence of
medical hardware, time from injury to first bacterial
culture with growth, multidrug resistance of organisms,
PRBC transfusion requirements within the first 24 hours
of injury, pathogen susceptibility to empiric antibiotics,
number of operating room visits prior to and on the
date of clinical diagnosis, and polymicrobial infection
status were examined as potential risk factors for per-
sistent infections in an univariate analysis (Table 7).
Specific bacterial organisms were not included as po-
tential risk factors in the analysis due to their role as
matching criteria for the cases and controls. Based
upon the results of the univariate analysis, the following
risk factors were significantly associated with persistent
infections: biofilm production (p < 0.0001), multidrug
resistance of organisms (p = 0.046), PRBC transfusion
requirements (p < 0.001), number of operating room visita-
tions (p = 0.022), anatomical site of infection (p = 0.003);
and polymicrobial infection status (p < 0.0001). A multi-
variate model failed to converge due to our limited
sample size.
Discussion
It is well-recognized that trauma-related infections often
result in considerable morbidity among military personnel.
Therefore, understanding potential risk factors for wound
infection persistence is critical for effective infection
management and to improve patient prognosis. Our
analysis compared data from 35 cases (SSTI wounds
with recurrent bacterial isolates at least 14 days apart)
with 69 controls (SSTI wounds with non-recurrent
isolates). The results of the univariate analysis sug-
gest that infection persistence is statistically associ-
ated with biofilm formation, along with the anatomical
site of the infected wound (non-groin/pelvis versus groin/
pelvis), multidrug resistance of pathogens, polymicrobial








Acinetobacter baumannii 79 (24.0) 36 (30.3)
Pseudomonas aeruginosa 78 (23.7) 35 (29.4)
Escherichia coli 28 (8.5) 23 (19.3)
Klebsiella pneumoniae 26 (7.9) 1 (0.8)
Staphylococcus aureus 10 (3.0) 7 (5.9)
Other 108 (32.8) 17 (14.3)
Total Bacterial Isolates 329 119
SSTI–skin and soft-tissue infections.
1Data collected from all levels of care: Landstuhl Regional Medical Center,
United States military medical treatment facilities, and
post-hospitalization follow-up.
Table 5 Infections due to multidrug-resistant (MDR)




Patients2 (N = 25)
SSTI Control
Patients2 (N = 60)
Acinetobacter
baumannii
Total Infections 9 21
MDR 9 (100) 21 (100)
Pseudomonas
aeruginosa
Total Infections 10 24
MDR 0 2 (8.3)
Escherichia coli Total Infections 8 12
ESBL-producing 6 (75.0) 10 (83.3)
Klebsiella
pneumoniae
Total Infections 1 1
ESBL-producing 1 (100) 1 (100)
Staphylococcus
aureus
Total Infections 3 2
MRSA 2 (66.7) 0
ESBL-extended-spectrum β-lactamase; MRSA-methicillin-resistant Staphylococ-
cus aureus; SSTI-skin and soft-tissue infections.
1Data are on a per patient basis and are collected from all levels of care:
Landstuhl Regional Medical Center, United States military treatment facilities,
and post-hospitalization follow-up.
2Eight patients with multiple infected wounds were utilized as both cases
and controls.
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infections, large volume PRBC transfusions, and the num-
ber of operating room visits leading up to the clinical
diagnosis of the infection. However, pathogen susceptibi-
lity to empiric antibiotics and presence of medical hard-
ware were not significant risk factors for persistent
infections.
Despite the multitude of scientific literature available
with biofilm data, there is a lack of clinical studies exa-
mining the role of biofilm formation as a risk factor for
persistent wound infections. Consistent with our find-
ings, studies assessing the relationship of biofilm forma-
tion and infection persistence in urinary tract infections
demonstrated a strong correlation between these two
factors [39,40]. To the best of our knowledge, the
current analysis provides the first statistical data linking
bacterial production of biofilms with the persistence of
traumatic wound infections and corroborates earlier re-
ports on the potential virulence of the bacterial biofilm
phenotype [25]. Biofilm formation, in our analysis, was
largely attributed to multidrug-resistant A. baumannii,
which corresponds to a prior study reporting a statistical
increase in the proportion of A. baumannii isolates that
were biofilm-producing and multidrug-resistant (73%)
when compared to P. aeruginosa (57%) [41]. In addition,
a recent analysis utilized clinical isolates collected from
patients including military personnel admitted to a U.S.
MTF to evaluate biofilm formation. Overall, 61% of
isolates produced biofilms, which were predominantly
associated with MDROs, including A. baumannii. It was
also determined that biofilm-producing isolates were
more commonly collected from wound sites (e.g., bone
and soft-tissue) compared to urine and blood [25].
Furthermore, the direct involvement of the A. baumannii
bap gene in biofilm formation and maturation on
medically-relevant abiotic surfaces (e.g., polypropylene,
polystyrene, and titanium) has been suggested [42].
The bap gene carriage is widespread among A. bau-
mannii isolates and may contribute to increased biofilm
formation; however, in the absence of data elucidating
in vivo gene expression, our data do not suggest carriage of
this gene by infecting isolates is sufficient to constitute a
risk factor for persistent infections. Moreover, confocal mi-
croscopy visualization of biofilm formation by bap-negative
isolates suggests a redundancy of mechanisms for biofilm
Table 6 Biofilm results, no. (%), on a per wound basis
Bacterial Isolates Biofilm Formation Total SSTI Case Wounds (N = 35) SSTI Control Wounds (N = 69) p-value
Acinetobacter baumannii Positive 19 (18.3) 12 (34.3) 7 (10.1) <0.0001
Negative 17 (16.4) 0 17 (24.6)
Pseudomonas aeruginosa Positive 34 (32.7) 12 (34.3) 22 (31.9) 0.543
Negative 2 (1.9) 0 2 (2.9)
Escherichia coli Positive 11 (10.6) 6 (17.1) 5 (7.3) 0.064
Negative 10 (9.6) 1 (2.9) 9 (13.0)
Klebsiella pneumoniae Positive 2 (1.9) 1 (2.9) 1 (1.5) NA
Negative 0 0 0
Staphylococcus aureus Positive 9 (8.7) 3 (8.6) 6 (8.7) NA
Negative 0 0 0
NA-not applicable; SSTI-skin and soft-tissue infections.
Table 7 Univariate odds ratio analysis for persistent
wound infection risk factors among deployment-injured
U.S. service members















Biofilm production 29.49 6.24-infinity <0.0001
PRBC requirements





Number of OR visits prior to
and on date of infection
diagnosis
2.05 1.09-4.28 0.022
Polymicrobial Infection 69.71 15.39-infinity <0.0001
Presence of medical devices
in the anatomic region of
the wound infection
1.05 0.35-3.17 0.925
OR-operating room; PRBC-packed red blood cells plus whole blood;
U.S.-United States.
1Characteristics are on a per wound basis.
2The odds ratios for continuous predictors estimate the change in odds for a
unit increase in the continuous predictor.
3Defined by demonstrating resistance to three or more antibiotic classes
(aminoglycosides, β-lactams, carbapenems, and fluoroquinolones) or
producing either extended spectrum β-lactamases or Klebsiella pneumoniae
carbapenemases [33].
4Blood product transfusion data is on a per patient basis.
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formation in A. baumannii. Nonetheless, it should be noted
that this analysis was limited by the infrequency of bap-
negative isolates.
In general, implantation of medical devices (e.g., materials
for wound stabilization, catheters, and joint prosthetics) has
been frequently associated with the production of biofilms
and subsequent infections in both military and civilian pop-
ulations [12,13,23-25,29]. Therefore, it was surprising that
the presence of medical hardware was not statistically
significant in the univariate model. One explanation could
be the low number of wounds (e.g., open fractures) that
required the implantation of medical hardware (~20%)
among both the cases and controls; thus, limiting the
power of the analysis. In addition, information on medical
hardware was not collected prospectively, which introduces
the biases and limitations related to retrospective data ana-
lysis. Furthermore, the date of medical device implantation
was an estimation based upon radiology reports, so the dir-
ect association of bacterial isolates with the hardware re-
mains uncertain. Lastly, data on medical devices in the
clinical records were not specific as to exact anatomic sites
(e.g., elbow and knee), but provided a more general location
(e.g., limbs). As a result, it cannot be definitively known if
the site of hardware implantation was the same site of in-
fection. Nonetheless, in the absence of medical hardware,
contamination of soft-tissue wounds by foreign bodies also
provides a suitable substrate for biofilm growth and impacts
the effectiveness of treatment. In particular, patients treated
exclusively with targeted antimicrobial therapy, and not in
conjunction with the removal of foreign bodies from in-
fected sites, are likely to develop persistent infections when
biofilms are involved [28].
One concern of clinicians in both military and civilian
settings is that the inherent tolerance of pathogens
encased in biofilms to antimicrobial agents, along with a
slow growth rate, creates opportunities for the transmis-
sion of resistance markers and subsequent increased
prevalence of MDROs in hospital settings. A recent ana-
lysis examined surveillance cultures collected from
wounded military personnel at LRMC and U.S. MTFs
and reported sustained colonization levels of multidrug-
resistant gram-negative organisms over a three-year
period (6.6% and 12.4%, respectively) [43]. Better under-
standing of biofilm-producing pathogens may provide
data to improve infection control strategies and reduce
the transmission of MDROs.
Moreover, infection persistence further add to the
large amount of hospital resources (approximately two-
thirds) necessary to manage extremity injuries among
wounded military personnel during the initial inpatient
period and hospital readmission. In particular, the re-
source cost of inpatient care and rehospitalization for
military personnel with extremity injuries was estimated
to be approximately $667 and $139 million, respectively,
during the conflicts in Iraq and Afghanistan [7]. Interven-
tions designed to effectively mitigate biofilm formation
might significantly reduce persistence among patients with
wound infections. Presently, antimicrobial methods and
control agents to eradicate biofilm pathogens are generally
unsuccessful [13,22].
Polymicrobial infection was identified in this study to be
a significant risk factor for relapsing infection in SSTIs. In
contrast to wound infections involving a single species, the
synergy between microorganisms with polymicrobial infec-
tions has been shown to increase bioburden, severity of
infection, increased antimicrobial resistance, and enhanced
inflammatory host responses within wounds [44-47]. Al-
though these studies did not fully address whether biofilm
formation, also associated with persistence, was enhanced
during polymicrobial infection, it seems probable that
these interactions between organisms that influence other
virulence properties would also have an effect on biofilm
formation. Given the observed association between polymi-
crobial infection and infection persistence, future studies
should evaluate interactions between organisms, such as
A. baumannii and common co-pathogens to assess the ef-
fects that this may have on virulence properties including
biofilm formation and chronicity of infection.
It should be noted there are limitations to our study
that should be considered. As previously discussed, the
analysis was limited by the small number of bap-nega-
tive isolates and wounds that required the implantation
of medical hardware. In addition, the statistical power of
the risk factor analysis was impacted by the overall, small
sample size. Specifically, when the data were examined in a
multivariate analysis, the model failed to converge due to
the small number of observations within each matched
strata groups when analyzed in combination with the other
potential risk factors. Since cultures were obtained at the
discretion of medical providers, ascertainment bias could
have resulted from preferential culturing of patients with
clinical infections, thus missing indolent or subacute bac-
terial colonization among less affected patients. However,
our study by design examined patients who met the NHSN
definition of clinical infection. Likewise, a misclassification
bias could have occurred if control wounds were subclini-
cally colonized with bacteria and not discovered after the
initial clinical infection due to lack of culturing. Nonethe-
less, as elegantly demonstrated in the literature, enforce-
ment of negative cultures among controls of a case–control
study can introduce a severity of illness bias, which has a
more severe effect on the odds ratios than does misclassifi-
cation bias [48]. Furthermore, biofilm testing has not been
standardized and the available methods do not evaluate
biofilm formation in identical manners. Consequently, the
results of biofilm analyses may vary depending on the
methodology. Among the currently available in vitro bio-
film models, the CV method utilized in our analysis has
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been widely reported in the literature and is considered to
be the de facto gold standard [49]. Since our study exa-
mined U.S. military casualties, our findings may not be
generalizable to all settings and populations; however, it
is notable that other armed conflicts unfortunately have
produced civilian casualties complicated by A. baumannii
wound infections [50].
Future work should seek to confirm the role of biofilm
formation by A. baumannii and other organisms as an
independent risk factor for the persistence or relapse of
wound infections. In addition, translational work is needed
to bring promising compounds into the clinical setting,
which target the prevention of biofilm development [51],
promote their dispersal [52,53], and eliminate persister
cells [54]. The potential for such approaches to eradicate
biofilm-mediated infections in vivo has recently been de-
monstrated [55]. Given the breadth of human clinical infec-
tions that have been proposed to involve bacterial biofilms
[13,20], substantial savings in resources and iatrogenic mor-
bidity could be realized if such therapies allowed for current
durations of antimicrobial therapy to be reduced.
Conclusions
The results of our analysis indicate that the production
of biofilms is significantly associated with the persistence
of wound infections. To the best of our knowledge, these
are the first data directly linking biofilm formation with
persistent wound infections. These findings indicate the
importance of biofilms in infection management. Fur-
ther analyses with a larger study population are needed
to validate our data and corroborate biofilm formation
as an independent risk factor for persistent trauma-
related infections. In addition, the parameters of polymi-
crobial infections, multidrug resistance, operating room
visitations, and large volume PRBC transfusions within
the first 24 hours warrant investigation as to their role
in the persistence of trauma-related infections.
Additional files
Additional file 1: Figure S1. Polymerase chain reaction (PCR) screening
of the biofilm-associated protein (bap) gene in clinical isolates of Acineto-
bacter baumannii. Seventy-six A. baumannii clinical isolates were screened
for the presence of the bap gene using primer BapF (5′ tag gga ggg tac
caa tgc ag) and BapR (5′ tca tga ttt gat gct gca gcg ata a). The bap gene
was amplified under the following conditions: 95°C for two minutes, 95°C
for 30 seconds, 61°C for 30 seconds, 68°C for one minute (times 30 cycles),
and 68°C for two minutes. The PCR products were separate in 1% Agarose
gel. A. baumannii ATCC strain 17978, a bap positive strain, was used as the
positive control. A clinical isolates of Escherichia coli was used as a negative
control.
Additional file 2: Figure S2. Visual analysis and comparison of biofilms
formed by clinical isolates of Acinetobacter baumannii screened for the
biofilm associated protein (bap) gene. Representative confocal laser
microscopy images of biofilms (20×) formed by clinical strains of A.
baumannii after 24 hours of growth in chamber slides stained with a
live/dead viability stain (Molecular Probes). Clinical strains confirmed
by polymerase chain reaction as bap positive (B-C) along with the bap
positive control (A) formed highly dense and homogenous biofilms,
whereas the bap negative clinical strains (D-F) formed less dense
biofilms with a more heterogeneous phenotype.
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